Psychedelic Bulletin #148 (Pα+)
- Notes from the Conference Call: Cybin’s Deuterated Psilocybin Analog Results
- Federal Appeals Court Throws Lifeline to Psilocybin Rescheduling Effort
- UK Report on Barriers to Research with Controlled Drugs Expected to Publish Soon
- Meta Ignores its Oversight Board’s Suggestions Regarding Ketamine Ads
- ‘Mushroom Pilot’ Case Sparks Soul-Searching
- Leading UK Psychedelic Drug Policy Reform Group Rebrands, Founder Mired by Arrest
- NIH to Establish and Fund a National Cannabis Research Centre
- New NIDA Grant Opportunity: Psychedelics for Substance Use Disorder
- Ethics Approval for Study of Psychedelics in Romantic Relationships
- Other Headlines and Weekend Reads
- Otsuka completes acquisition of Mindset Pharma
- Mass. psychedelics ballot initiative collects over 75,000 signatures, could go before voters next year
- MindMed patent on psilocybin + escitalopram granted
- COMPASS Pathways CFO steps down
- 5-HT2C also induces head-twitch response?
- Oakland-based group file California psychedelic ballot initiative
- Weekend Reading: The app that promised an NHS ‘revolution’ then went down in flames
- Reset Pharma receives Safe to Proceed notification from FDA
- Around the web
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. If you’re reading this, you’re one of our earliest subscribers: thank you for joining us.
Notes from the Conference Call: Cybin’s Deuterated Psilocybin Analog Results
Earlier this week we shared some initial reactions to Cybin’s interim topline data from its Phase 2a study of CYB003, its deuterated psilocybin analog candidate. You can read that here.
Since then, we have been mulling over the results a little more. We also joined the company’s conference call. Our notes…
CEO Doug Drysdale describes their deuteration as “optimising pharmacokinetics”, with the goal of generating faster onset of psychedelic effects and a shorter in-clinic time. Later, he mentioned that faster onset could also be handy if patients are anxious about the psychedelic experience, as the time between ingestion and the onset of effects would be shorter.
Drysdale was also keen to highlight the company’s IP portfolio, which is claimed to be the largest in the psychedelic drug development space. The company has 33 granted patents, with over 170 pending. As many readers are aware, deuteration is sometimes employed as a strategy to obtain patent protection.
CMO Amir Inamdar was keen to remind listeners that all patients were permitted to remain on antidepressant medications, provided they were on a stable dose. This is often not the case in psychedelic clinical trials, where participants are usually required to taper off...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks